(MedPage Today) — The FDA expanded the indication of inebilizumab (Uplizna) to include generalized myasthenia gravis (gMG), Amgen announced Friday.
The drug is now approved to treat gMG in adults who are anti-acetylcholine receptor (AChR) or…
Source link : https://www.medpagetoday.com/neurology/generalneurology/118998
Author :
Publish date : 2025-12-12 21:56:00
Copyright for syndicated content belongs to the linked Source.
